The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.

A microstructured hemostat comprising multiple layers of microstructure, each layer characterized by one or more length scales, is described. Microstructured hemostats of the present invention, can reduce the time for blood coagulation, control the morphology of the coagulation, and provide a novel diagnostic platform for evaluation of coagulation function from a morphological perspective.

Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

This present invention relates to drug eluting polymers, including novel biodegradable drug eluting polymers, which are added to the surface of a medical device to treat device associated complications and to deliver drug locally around the device. Methods of making polymers, for example, drug-eluting polymers, polymer compositions, and materials used therewith also are provided. The drug eluting polymers are obtained from the polymerization of macromonomers made of a connecting moiety, a biodegradable moiety and a cross-linkable moiety that are liquids at a temperature of 10° C. to 40° C.

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

The disclosure provides a hemostatic fabric containing trypsin, wherein the hemostatic fabric comprises molecular sieve/fiber composite and trypsin; molecular sieve/fiber composite comprises molecular sieves and a fiber; the molecular sieves are independently dispersed on a fiber surface of the fiber without agglomeration and directly contact the fiber surface; a surface of the molecular sieve contacted with the fiber is an inner surface, and a surface of the molecular sieve uncontacted with the fiber is an outer surface; growth-matched coupling is formed between the molecular sieves and the fiber on the inner surface of the molecular sieves; the inner surface and outer surface are composed of molecular sieve nanoparticles. In the present disclosure, trypsin is specifically combined with the molecular sieve/fiber composite, which maintains a high procoagulant activity, thereby obtaining a hemostatic fabric with excellent coagulation effect.

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

The present invention relates inter alia to an apparatus for providing a coiled collagen carrier. An apparatus according to the invention preferably comprises a device for applying moisture to a collagen carrier prior to coiling of the collagen carrier and a coiling device. The coiling device preferably comprises rotatable gripping means for gripping the collagen carrier along an edge and coiling the collagen carrier, and a support device supporting the collagen carrier while being coiled. In another aspect, the invention relates to a production facility wherein an apparatus according to invention is arranged.

Peptide dendrimers and agents are described, which can be used for polymerising fibrinogen and as haemostatic agents. The peptide dendrimers comprise a branched core, and a plurality of fibrinogen-binding peptides separately covalently attached to the branched core. The branched core comprises: i) from two to ten multi-functional amino acid residues, wherein each fibrinogen-binding peptide is separately covalently attached to a multi-functional amino acid residue of the branched core; il) a plurality of multi-functional amino acid residues, wherein one or more fibrinogen-binding peptides are separately covalently attached to each of at least two adjacent multi-functional amino acid residues of the branched core; Hi) a plurality of multi-functional amino acid residues, wherein two or more fibrinogen-binding peptides are separately covalently attached to at least one of the multi-functional amino acid residues of the branched core; iv) a plurality of multi-functional amino acid residues, wherein two or more multi-functional amino acid residues are covalently linked through a side chain of an adjacent multi-functional amino acid residue; or y) a single multi-functional amino acid residue, and a fibrinogen-binding peptide is separately covalently attached to each functional group of the multi-functional amino acid residue, The. multi-functional amino acid residues comprise tri- or tetra-functional amino acid residues, or tri- and tetra-functional amino acid residues, or the single multi-functional amino acid residue is a tri- or tetra-functional amino acid residue.